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Maternal  vaccination  is an important  area  of  research  and  requires  appropriate  and  internationally  com-
parable  deﬁnitions  and  safety  standards.  The  GAIA  group,  part of  the  Brighton  Collaboration  was  created
with  the mandate  of proposing  standardised  deﬁnitions  applicable  to  maternal  vaccine  research.  This
study  proposes  international  deﬁnitions  for  neonatal  infections.
The neonatal  infections  GAIA  working  group  performed  a literature  review  using  Medline,  EMBASE
and  the  Cochrane  collaboration  and  collected  deﬁnitions  in  use  in  neonatal  and  public  health  networks.
The  common  criteria  derived  from  the  extensive  search  formed  the  basis  for a consensus  process  that
resulted  in  three  separate  deﬁnitions  for neonatal  blood  stream  infections  (BSI),  meningitis  and  lower
respiratory  tract  infections  (LRTI).  For each  deﬁnition  three  levels  of evidence  are proposed  to  ensure  the
applicability  of  the deﬁnitions  to  different  settings.
Recommendations  about  data  collection,  analysis  and  presentation  are  presented  and  harmonized
with  the  Brighton  Collaboration  and  GAIA  format  and  other existing  international  standards  for  study
reporting.
© 2016  Published  by  Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
1. Preamble
1.1. Need for developing case deﬁnitions and guidelines for data
collection, analysis, and presentation for neonatal infections as an
adverse event following immunisation
Considering the enormous public health beneﬁt that can poten-
tially be derived by vaccinating women in pregnancy to protect
their newborns against speciﬁc infections, it is now imperative to
establish safety and efﬁcacy standards in this area. This includes
the need to develop deﬁnitions for neonatal infections. Such deﬁ-
nitions need to be ﬂexible enough to reﬂect changes in the pattern
of infections that may  occur following vaccination and to include
infections as possible adverse events [1,2]. Considering that vacci-
nation may  delay the onset of infections from the neonatal period
to later in infancy, the deﬁnitions also need to be applicable to the
young infant.
Providing standardised deﬁnitions of neonatal infections is
equally relevant for global efforts to address child mortality since
the majority of deaths in children less than ﬁve years now occur
in the neonatal period and neonatal infections are the third most
common cause of death in newborns [3]. The majority of deaths
occur in low and middle-income countries (LMIC) and therefore
standardised deﬁnitions for global use must speciﬁcally reﬂect the
needs of LMICs. Global deaths from neonatal sepsis and other infec-
tions were estimated to be 328,000 and 342,000 in 1990 and 2013,
respectively (age-standardised death rates 4.7 and 4.9 per 100,000,
respectively) [4]. The other most common types of fatal neona-
tal infections in 2013 were lower respiratory infections (196,500
deaths), diarrhoeal diseases (44,800), tetanus (26,000), meningitis
(20,600), and malaria (16,800) [4].
A variety of deﬁnitions for neonatal infections have been pro-
posed and applied in both community and hospital studies (for
example from the Young Infant Clinical Study Group (YICSG)) [5],
or as part of verbal autopsy studies [6].
In high-income countries, neonatal intensive care has advanced
dramatically over the last decades. Neonatal infections cause a
signiﬁcant burden of morbidity and mortality in the extremely
preterm population in these settings. As a result, neonatal
networks around the world have produced many case deﬁnitions
for infections, especially focusing on preterm infants. The better
known case deﬁnitions are from the National Institute of Child
Health and Human Development Neonatal Research Network
(NICHD) [7], Australian and New Zealand Neonatal Network
(ANZNN) (https://npesu.unsw.edu.au/data-collection/australian-
new-zealand-neonatal-network-anznn), European Neonatal Net-
work (ENN) [8], the Vermont-Oxford-Network (VON) (https://
public.vtoxford.org) and the neonatal infection network (neonIN;
www.neonin.org.uk). Some infectious disease networks have
focused speciﬁcally on healthcare-associated infections, such as
neoKISS [9]. With a similar drive to monitoring hospital associated
infections, other organisations such as the Centers for Diseases
Control (CDC) [10], the European Centre for Disease Control (ECDC)
(http://ecdc.europa.eu/en/healthtopics/Healthcare-associated
infections/point-prevalence-survey/Pages/Point-prevalence-
survey.aspx) and the European Medicine Agency (EMA) (http://
www.ema.europa.eu/docs/en GB/document library/Report/2010/
12/WC500100199.pdf) have proposed yet more neonatal infection
deﬁnitions.
In the neonatal period, the immaturity of the immune sys-
tem, particularly in premature infants, confers distinctive clinical,
physical and outcome characteristics to infections compared with
other age groups: neonates are more vulnerable to a broad range
of pathogens, including those of generally low virulence such as
Listeria, paraechoviruses or Candida. Different pathogens such as
bacteria, viruses, fungi or parasites often present in a clinically
indistinguishable pattern in neonates, and localised infections may
present with systemic signs making the clinical diagnosis difﬁcult
and often impossible without imaging conﬁrmation and/or labo-
ratory support. Moreover, a number of non-infectious syndromes,
such as respiratory distress syndrome in the premature infant,
inborn errors of metabolism and congenital malformations such as
serious cardiac anomalies, have initial clinical presentations similar
to severe infections [11].
Even when laboratory tests are available, diagnostic tools
to guide clinicians are limited. Traditional blood culture meth-
ods lack sensitivity, particularly in neonates where only small
samples can be obtained. This leads to a high number of neg-
ative results, leaving a large percentage of bacterial infections
microbiologically unconﬁrmed [12]. Whilst the diagnosis of some
entities such as HIV and CMV  has beneﬁted from the use of novel
PCR-based molecular diagnostic tools, this has not happened for
all neonatal infections. Interpretation of molecular results from
non-sterile samples, such as nasopharyngeal aspirates, can be
problematic [13].
The lack of a standardised clinical or laboratory diagnosis for
neonatal infections explains the heterogeneity in the neonatal
infection deﬁnitions in current use, particularly for probable blood-
stream infections [14].
There is currently no uniformly accepted deﬁnition of neona-
tal infections following immunizations. However, the development
of standardised deﬁnitions is now essential in order to facilitate
comparability of data and outcomes across clinical trials and epi-
demiological surveillance studies in which women have received
vaccines in pregnancy as well as other clinical trials and interven-
tions aimed at reducing neonatal morbidity and mortality.
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1.2. Methods for the development of the case deﬁnition and
guidelines for data collection, analysis, and presentation for
neonatal  infections as an adverse event following immunisation
Following the process described in the overview paper [15],
the Brighton Collaboration – GAIA: Neonatal Infections Working
Group was formed in 2015 and included members with clini-
cal, academic, public health, and vaccine industry background.
The composition of the working and reference group as well
as results of the web-based survey completed by the reference
group with subsequent discussions in the Working Group can
be viewed at: http://www.brightoncollaboration.org/internet/en/
index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
lines, a literature search was performed using Medline, Embase
and the Cochrane Libraries, the search terms are available in
Appendix 1.
The  search resulted in the identiﬁcation of 4422 references.
Only references with full abstracts (in English language) were
included. All abstracts were screened for possible reports of neona-
tal infections. 1205 articles with potentially relevant material were
reviewed in more detail. This review resulted in a detailed summary
of 432 articles, including information on the diagnostic criteria
or case deﬁnitions used. Case reports, editorials and letters were
excluded. Where relevant a description of the vaccine used, the
time interval since immunisation, and any other symptoms were
extracted. Multiple key references were hand searched and def-
initions from existing neonatal networks, infection surveillance
networks and websites of public health organisations such as the
Centers for Disease Control (CDC), the European Centre for Disease
Control (ECDC) and the European Medicine Agency (EMA) were also
searched for neonatal and perinatal infection deﬁnitions.
Across the different manuscripts selected, a large number of
deﬁnitions were found with a variable number and type of clin-
ical, laboratory and microbiological criteria. The quality of the
manuscripts was heterogeneous but this review did not grade the
evidence as it was not considered to be relevant for the task of
extracting the deﬁnitions used.
The deﬁnitions from the manuscripts were extracted and
entered into spreadsheets listing clinical, laboratory and radiolog-
ical criteria by 14 members of the group independently and then
reviewed for consistency by the coordinator (SV). The data were
separated according to the syndrome described: sepsis, meningitis
and respiratory tract infections and congenital infections. Percent-
ages of the clinical and laboratory indicators were calculated. The
syndromes were not separated according to single pathogens or
class of pathogens.
The  data extracted from the published literature were col-
lected recognizing the limitation that each study reported different
data and deﬁnitions for the clinical or laboratory signs and these
were not always speciﬁed nor clearly described. The studies from
neonatal units in high-income countries were reporting both clin-
ical and laboratory conﬁrmed infections while community studies
from middle- or low-income countries used mostly clinical def-
initions. This heterogeneity made data extraction a somewhat
subjective exercise. Proposed deﬁnitions for speciﬁc congenital
infections were also discussed, but were eventually excluded from
this guideline and recommended for consideration as a speciﬁc
group of deﬁnitions for a future Brighton collaboration Working
Group.
The results of this work were presented to the Working Group
together with the standard deﬁnitions currently in use from the
aforementioned networks and the group discussed the deﬁnitions
in a series of teleconferences until consensus was obtained.
1.3. Rationale for selected decisions about the case deﬁnition of
neonatal  infections as an adverse event following immunisation
For  the purpose of this guideline the term “infection” includes
neonatal bacteraemia and sepsis (of early or late onset), meningitis,
pneumonia and other respiratory infections such as bronchioli-
tis, caused by bacteria, parasites, viruses or fungi. Localised eye
and ear infections were excluded from these guidelines as were
encephalitis, urinary tract infections and intestinal infections. The
term “neonatal” includes infants from birth (day 0) up to and
including 28 postnatal days.
The term “neonatal infection” was  chosen to include differ-
ent infection syndromes during the neonatal period (proven blood
stream infections, probable blood stream infections, meningitis and
respiratory tract infections).
Ultimately,  the group reached agreement on 3 separate def-
initions for neonatal infections, each with 3 or more diagnostic
levels. It is important to emphasise that within the deﬁnition con-
text, however, the diagnostic levels must not be misunderstood as
reﬂecting different grades of clinical severity. They instead reﬂect
diagnostic certainty. The case deﬁnition has been formulated such
that the Level One deﬁnition is highly speciﬁc for the condition.
As maximum speciﬁcity normally implies a loss of sensitivity, one
or two  additional diagnostic levels have been included in the def-
inition, offering a stepwise increase of sensitivity from level one
to level three, while retaining an acceptable level of speciﬁcity at
all levels. In this way it is hoped that all possible cases of neonatal
infections can be captured, regardless of the setting or population
in which they are being assessed. This is of particular relevance in
LMICs where the resources available to assess events, e.g. labora-
tory facilities, may  be more limited.
1.3.1. Rationale for individual criteria or decisions made related
to  the case deﬁnition
1.3.1.1.  Neonatal invasive blood stream infections. The GAIA neona-
tal infections Working Group included in level 1 the microbiological
conﬁrmation of infection as this is the recognised diagnostic gold
standard. It was decided to use the term “validated” method of
identiﬁcation because it was recognised that this is a rapidly chang-
ing ﬁeld, especially with regard to molecular tests. It is hoped that
this will allow the deﬁnition to be as inclusive as possible as these
methods continue to advance.
The  group opted to include a list of organisms commonly con-
sidered non-pathogenic (often called “skin commensals”), but still
capable of causing opportunistic infections in certain situations, for
example, in the presence of central lines, as well as a list of recog-
nised pathogens in order to reduce uncertainty and differences in
reporting.
The number of clinical criteria was  chosen by reviewing the
available deﬁnitions in the literature and by consensus. It was
decided to include a level 3 deﬁnition based solely on clinical signs
and taken from a systematic review of studies that reported clini-
cal signs predictive of severe illnesses or mortality in young infants
aged 0–59 days, endorsed by the World Health Organization (WHO)
[16]. The limited set of clinical signs for which extensive evidence
supporting their value exists was reported to have high sensitivity
and reasonable speciﬁcity. This ensures that the case deﬁnition has
relevance in all populations and settings.
With regard to the criterion of abnormal white cell count (WCC),
it is recognised that ethnic variations exist, for example many
African Americans have a WCC  that is persistently below the normal
range for people of European descent, a condition called “benign
ethnic neutropenia” [17]. This should be considered when evaluat-
ing a case.
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 1.3.1.2. Neonatal meningitis. As above, the GAIA neonatal infec-
tions Working Group included in level 1 the microbiological
conﬁrmation of infection as this is the recognised diagnostic gold
standard.
In recognition that delays in undertaking a lumbar puncture
may  mean that antibiotics have already been given before CSF
is obtained, which may  make microbiological conﬁrmation less
likely, the group included a deﬁnition based on the presence of
CSF pleocytosis. CSF pleocytosis was deﬁned as ≥20 cells/mm3 for
≤28 day-olds and ≥10 cells/mm3 for 29–89 day-olds based on data
from large studies [18,19] with no adjustment made for traumatic
taps [20].
1.3.1.3. Respiratory tract infections (RTI). The GAIA neonatal infec-
tions Working Group provided a single deﬁnition for RTI which
aimed to include bacterial, fungal and viral pathogens to allow ease
of use. The different pathophysiology of viral and bacterial or fungal
infections is reﬂected in the use of diagnostic imaging. Radiographic
features (e.g. lobar inﬁltrate) were accepted without microbiolog-
ical conﬁrmation for bacterial and fungal infections, but viral low
respiratory tract infections required laboratory conﬁrmation, even
in the presence of X-ray ﬁndings consistent with a viral diagno-
sis.
The number of clinical criteria chosen arose from the consensus
of the group after careful review of available evidence and current
deﬁnitions in use.
The Working Group were aware of the proposed WHO  candidate
case deﬁnitions for RSV vaccine efﬁcacy trials and believe that both
sets of guidelines are consistent.
1.3.2. Inﬂuence of treatment on fulﬁlment of case deﬁnitions [21]
In the context of infection a response to antimicrobial treat-
ment might be considered towards fulﬁlment of the neonatal
infections case deﬁnition. However, the Working Group decided
against this. A treatment response or its failure is not in itself
diagnostic and may  depend on variables such as clinical status,
time to initiation of treatment, other clinical parameters and for
many infections, particularly viral, no treatment is currently avail-
able.
Inﬂammatory markers were included although it was recog-
nised that viral infections often are not accompanied by an
inﬂammatory response and newborns often do not present a
strong inﬂammatory response, particularly extremely preterm
infants.
1.3.3. Timing post immunisation
Speciﬁc time frames for onset of symptoms following immun-
isation are not included because there are many factors that may
inﬂuence the impact of vaccination in pregnancy on events in the
newborn period. Such factors include the vaccine given, the length
of gestation at vaccination of the mother and at birth, the pres-
ence of pre-existing immunity and concomitant illnesses in the
newborn.
We postulate that a deﬁnition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
independent from the exposure (e.g. immunisations). Therefore, to
avoid selection bias, a restrictive time interval from immunisation
to the onset of neonatal infections should not be an integral part
of such a deﬁnition. Instead, where feasible, details of this interval
should be assessed and reported as described in the data collection
guidelines.
Further, events often occur outside the controlled setting of
a clinical trial or hospital. In some settings it may  be impossi-
ble to obtain a clear timeline of the event, particularly in less
developed or rural settings. In order to avoid selecting against
Table 1
Neonatal invasive blood stream infections: bacterial/fungal/viral.
LEVEL 1 LEVEL 2 LEVEL 3 [22]
Recognised pathogena
identiﬁed using a
validated method
and from a normally
sterile siteb
If an organism
normally considered
non-pathogenic is
isolated from blood
culturesa: Level 1
requires its
identiﬁcation from at
least 2 blood cultures
taken from two
different sites, or at 2
different times, PLUS
1 of the criteria as
per level 2 of
evidence
Not meeting Level 1 of
evidence
AND
3 or more criteria:
•  Temperature ≥37.5 ◦C or
<35.5 ◦Cf
• Tachycardiad or new or
more frequent episodes of
bradycardiad
• New or more frequent
episodes of apnead or
increased oxygen
requirement or increased
requirement for
ventilatory support
• Lethargy or moving only
when stimulated or
hypotonia or irritability
•  Difﬁculty in feeding or
abdominal distention
• Pallor or poor
perfusiondor hypotensiond
• Abnormal White Cell
Countd or I/T ratio >0.2
• Abnormal platelet count d
• Increasede inﬂammatory
markers (CRP,
procalcitonin)
• Metabolic acidosis as
deﬁned by a base excess
(BE)d
Not meeting Level
1  or 2 of evidence
AND
2 or more of the
following criteria:
• Temperature
≥37.5 ◦C or
<35.5 ◦Cf
• Tachypnead or
severe chest
indrawing or
grunting or
cyanosis
•  Change in level of
activity
•  History of feeding
difﬁculty
• History of
convulsions
a See list of pathogens and non-pathogens in Appendix 1.
b Sterile site: blood, sterile urine (catheter urine or supra-pubic aspirate), pleural
ﬂuid, ascitic ﬂuid, broncho-alveolar lavage, bone biopsy, synovial ﬂuid.
d Deﬁnitions: Apnea: pause in breathing >20 s; CRP or calcitonin levels above the
local  normal standards; Tachypnea/fast breathing: respiratory rate >60 breaths per
minute; Tachycardia: heart rate >180 beats per minute; Bradycardia: heart rate
<100 beats per minute; c Poor perfusion: CRT >2. d 4000 or >20,000 × 109 cells/L; Low
Platelets/Thrombocytopenia: <100,000 × 109/L; Metabolic acidosis: <−10 mmol/L
(−10 mEq/L)
e Increased according to locally deﬁned and validated reference ranges.
f Also refer to Brighton collaboration case deﬁnition for fever [23].
such cases, the case deﬁnition avoids setting arbitrary time
frames.
1.3.4. Differentiation from other (similar/associated) disorders
Using the level 2 or 3 of evidence there is risk that the above
deﬁnitions will include other neonatal pathologies such as con-
genital heart diseases or inborn errors of metabolism within the
blood stream infections (BSI) and meningitis deﬁnitions or even
respiratory distress syndrome and transient tachypnea of the new-
born in the most premature neonates within the RTI deﬁnition.
Congenital malformations and inborn error of metabolism are
relatively rare events however, and distinction based on clinical
response to treatment, laboratory investigations and imaging may
be possible in most settings.
1.4. Guidelines for data collection, analysis and presentation
The case deﬁnition is accompanied by guidelines, which are
structured according to the steps of conducting a clinical trial,
i.e. data collection, analysis and presentation. Neither case deﬁni-
tion nor guidelines are intended to guide or establish criteria for
management of ill infants, children, or adults. Both were developed
to improve data comparability.
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Table  2
Bacterial/fungal/viral meningitis.
LEVEL 1 LEVEL 2 LEVEL 3a LEVEL 3b
Recognised pathogena identiﬁed
using a validated method from
cerebrospinal ﬂuid (CSF)
If an organism normally
considered non-pathogenic is
identiﬁed from the CSF, LEVEL 1
of evidence additionally requires
all LEVEL 2 criteria: i.e. CSF
pleocytosis AND temperature
criteria AND 1 or more clinical
criteria
CSF pleocytosisd OR positive IgM
antibodies to a speciﬁc pathogen in the
CSF
AND
Recognised pathogena identiﬁed using
a  validated method from a normally
sterile siteb (other than CSF)
AND
Temperature ≥37.5 ◦C or <35.5 ◦Cc
AND
1 or more criteria:
•  History of convulsions
• Lethargy or irritability
•  Coma
• Apnead
• Bulging fontanel
•  Neck stiffness
CSF pleocytosisd
AND
NO d pathogena identiﬁed using a
validated method from a normally
sterile siteb
AND
Temperature ≥37.5 ◦C or <35.5 ◦Cc
AND
3 or more criteria:
•  History of convulsions
• Lethargy or irritability
• Coma
• Apnead
• Bulging fontanel
• Neck stiffness
No lumbar puncture done or no
sample available
AND
Temperature ≥37.5 ◦C or <35.5 ◦Cc
AND
4 or more criteria:
•  History of convulsions
• Lethargy or irritability
•  Coma
• Apnead
• Bulging fontanel
•  Neck stiffness
a See list of pathogens and non-pathogens in Appendix 1.
b Sterile site: blood, sterile urine (catheter urine or supra-pubic aspirate), pleural ﬂuid, ascitic ﬂuid, broncho-alveolar lavage, bone biopsy, synovial ﬂuid.
c Also refer to Brighton collaboration case deﬁnition for fever [23].
d CSF pleocytosis: ≥20 cells/mm3 for <28 day-olds and ≥10 cells/mm3 for 29–89 day-olds. # i–89 day-olds.
1.5. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
lines, review of the deﬁnition with its guidelines is planned on a
regular basis (i.e. every three to ﬁve years) or more often if needed.
2. Case deﬁnitions of neonatal infections
2.1. Neonatal invasive blood stream infections:
bacterial/fungal/viral
Table 1 presents the case deﬁnition for neonatal invasive blood
Stream Infections: bacterial/fungal/viral.
2.2. Bacterial/fungal/viral meningitis
Table 2 presents the case deﬁnition for bacterial/fungal/viral
meningitis.
2.3. Respiratory bacterial/fungal/viral infection
Table 3 presents the case deﬁnition for respiratory bacte-
rial/fungal/viral infection.
3. Guidelines for data collection, analysis and presentation
of neonatal infections
It was the consensus of the Brighton Collaboration GAIA Neona-
tal Infections Working Group to recommend the following guidelines
to enable standardised data collection, analysis, and presenta-
tion of information regarding neonatal infections in the context
of pregnancy vaccination. The availability of information may
vary depending upon resources, geographical region, and whether
the source of information is a prospective clinical trial, a post-
marketing surveillance or epidemiological study, or an individual
report of a neonatal infection.
Guidelines for the collection, analysis and presentation of
safety data in clinical trials of vaccines in pregnant women
are also available and should be referred to for more generic
guidance.
3.1. Data collection
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing the event as speciﬁed by country-speciﬁc data pro-
tection law.
(3) Name and contact information of the investigator responsible
for the subject, as applicable.
(4) Relation to the patient (e.g. immuniser [clinician, nurse], family
member [indicate relationship], other).
3.1.2. Vaccinee/control
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
3.1.2.1. Demographics.
(5) Case/study participant identiﬁers (e.g. ﬁrst name initial fol-
lowed by last name initial) or code (or in accordance with
country-speciﬁc data protection laws).
(6) Date of birth, age, and sex. With neonatal data disaggregated
from older infants.
(7) Gestational age, birth weight and methods used for their assess-
ment.
2 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.
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 Table  3
Respiratory bacterial/fungal/viral infection.
LEVEL 1 LEVEL 2 LEVEL 3 [24,25]
New or progressive or persistent inﬁltrate or
shadowing or ﬂuid in the intrapleural cavity or
interlobar ﬁssure on chest X-ray
AND
Recognised virusc identiﬁed using a validated assay
from an upper respiratory sample
OR
Recognised pathogena identiﬁed using a validated
method and from a normally sterile siteb
AND 3 or more criteria:
• Temperature ≥37.5 ◦C or <35.5 ◦Ce
• Tachypneac or Nasal ﬂaring or Chest indrawing or
Grunting
• Desaturations or increased oxygen requirements or
increased ventilator requirements or oxygen
saturation <95%
• Apneasc
• Increased respiratory secretions or Increased
suctioning requirements
• Cough or wheeze or crepitations
•  Increased CRP or procalcitonind
New or progressive or persistent inﬁltrate or
shadowing or ﬂuid in the intrapleural cavity or
interlobar ﬁssure on chest X-ray
AND 4 or more criteria:
• Temperature ≥37.5 ◦C or <35.5 ◦Ce
• Tachypneac or Nasal ﬂaring or Chest
indrawing or Grunting
•  Desaturations or increased oxygen
requirements or increased ventilator
requirements or oxygen saturation <95%
• Apneasc
• Increased respiratory secretions or Increased
suctioning requirements
• Cough or wheeze or crepitations
•  Increased CRP or procalcitonind
2 or more criteria:
Difﬁculty in
breathing/Tachypneac
• Severe chest indrawing
•  Nasal ﬂaring
• Grunting
• Wheezing
• Stridor
• Fever
a See list of pathogens and non-pathogens in Appendix 1.
b Sterile site: blood, sterile urine (catheter urine or supra-pubic aspirate), pleural ﬂuid, ascitic ﬂuid, broncho-alveolar lavage, bone biopsy, synovial ﬂuid.
c See list of deﬁnitions in Table 1.
d Increased according to locally deﬁned and validated reference ranges.
e Also refer to Brighton collaboration case deﬁnition for fever [23].
3.1.2.2. Clinical and immunisation history. For all cases and/or
all study participants, as appropriate, the following information
should be recorded:
(8) Mother: Maternal history of infections or risk factors for
infections (e.g. GBS colonisation, peripartum fever), indica-
tion whether any antimicrobials were used in pregnancy or
in labour, type and route of administration; underlying dis-
eases/disorders, type of delivery and indicate whether the
delivery occurred in a facility or at home, describe obstetric
care available in terms of basic or comprehensive; immunisa-
tion received in pregnancy with dates, type, batch and reaction
for all infections, available serology as applicable, any other
medications use during pregnancy including non prescription
medications.
(9) Newborn: report whether the newborn was admitted to hos-
pital and the type of facility (e.g. emergency department, ward,
neonatal unit) or was in the community. Indicate the level of
neonatal care available (e.g. ventilator support) and give the
type of neonatal care staff available and their level of training,
Indicate the presence of central lines, whether the newborn
received surgical interventions and their type.
(10) Newborn: Report the medication history (other than treat-
ment for the event described) including prescription and
non-prescription medication as well as medication, topi-
cal treatments, parenteral nutrition or treatment with long
half-life or long-term effect (e.g. immunoglobulins, blood
transfusion and immunosuppressants).
(11) Facility: indicate whether microbiology laboratory investi-
gations are available and describe the methods used for
bacterial identiﬁcation or the molecular techniques used to
identify organisms viral, fungal, parasitic or bacterial. Give an
indication of the quality control in place. Indicate whether bio-
chemistry, haematology and radiology facilities are available.
(12) Immunisation history (i.e. previous immunizations and any
adverse event following immunisation (AEFI)), in partic-
ular occurrence of neonatal infection after a previous
immunisation.
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3.1.3. Details of the immunisation
For all study participants, as appropriate, the following informa-
tion about pregnancy vaccination should be recorded:
(13) Date and time of immunisation(s), gestational age at the time
of immunisation. Context of immunisation (routine clinic, out-
break situation, clinical trial, etc.)
(14) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL,  0.5 mL,  etc.) and number of dose if
part of a series of immunizations against the same disease).
(15) The anatomical sites (including left or right side) of all immun-
izations (e.g. vaccine A in proximal left lateral thigh, vaccine B
in left deltoid).
(16) Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
size), oral, intranasal, other injection devices).
(17) Needle length and gauge.
3.1.4. The adverse event
(18) For all cases at any level of diagnostic certainty and for
reported events with insufﬁcient evidence, the criteria ful-
ﬁlled to meet the case deﬁnition should be recorded.
Speciﬁcally document:
(19) Clinical description of signs of neonatal infection and if there
was conﬁrmation of the infection (i.e. positive identiﬁcation
using validated method).
(20) Date/time of onset,3 ﬁrst observation4 and diagnosis,5 end of
episode6 and ﬁnal outcome.7
(21) Concurrent signs and diseases.
(22) Measurement/testing
• Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indicating
the severity of the event;
• Method of measurement (e.g. type of thermometer, oral or
other route, duration of measurement, etc.);
• Results of laboratory examinations, surgical and/or patho-
logical ﬁndings and diagnoses if present.
(23) Treatment given for neonatal infection, especially antimi-
crobials, including which antimicrobials (e.g. antibiotics,
antivirals, immunoglobulins), dosing and duration of treat-
ment.
(24) Outcome6 at last observation.
(25) Objective clinical evidence supporting classiﬁcation of the
event as “serious”8
(26) Exposures from 24 h before and after immunisation (e.g.
food, environmental) considered potentially relevant to the
reported event.
3 The date and/or time of onset is deﬁned as the time post immunisation, when
the ﬁrst sign or symptom indicative for neonatal infection occurred. This may  only
be possible to determine in retrospect.
4 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom indicative
for  neonatal infection can be used if date/time of onset is not known.
5 The date of diagnosis of an episode is the day post immunisation when the event
met  the case deﬁnition at any level.
6 The end of an episode is deﬁned as the time the event no longer meets the case
deﬁnition at the lowest level of the deﬁnition.
7 E.g. recovery to pre-immunisation health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
8 An AEFI is deﬁned as serious by international standards if it meets one or
more of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
requires inpatient hospitalisation or results in prolongation of existing hospitalisa-
tion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
anomaly/birth defect, (6) is a medically important event or reaction.
3.1.5. Miscellaneous/general
(27) The duration of surveillance for neonatal infection should be
predeﬁned based on
• Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
• Biologic characteristics of the vaccine-targeted disease;
• Biologic characteristics of neonatal infection including pat-
terns identiﬁed in previous trials (e.g. early-phase trials);
and
• Biologic characteristics of the vaccinee (e.g. nutritional sta-
tus, underlying disease like immunosuppressing illness).
(28) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. It should aim to con-
tinue to resolution of the event.
(29) Methods of data collection should be consistent within and
between study groups, if applicable.
(30) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines.
(31) Investigators of patients with neonatal infection should
provide guidance to reporters to optimise the quality and com-
pleteness of information provided.
(32) Reports of neonatal infection should be collected through-
out the study period regardless of the time elapsed between
immunisation and the adverse event. If this is not feasible due
to the study design, the study periods during which safety data
are being collected should be clearly deﬁned.
3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on neonatal infections to allow for comparability of
data, and are recommended in addition to the data analysed for the
speciﬁc study question and setting.
Reported events should be classiﬁed in one of the following ﬁve
categories including the three levels of diagnostic certainty. Events
that meet the case deﬁnition should be classiﬁed according to the
levels of diagnostic certainty as speciﬁed in the case deﬁnition.
Events that do not meet the case deﬁnition should be classiﬁed
in the additional categories for analysis.
Event classiﬁcation in 5 categories9
• Event meets case deﬁnition
(1) Level 1: Criteria as speciﬁed in the neonatal infections case
deﬁnition (separately for BSI, meningitis and RTI)
(2) Level 2: Criteria as speciﬁed in the neonatal infection case
deﬁnition (separately for BSI, meningitis and RTI)
(3) Level 3: Criteria as speciﬁed in the neonatal infections case
deﬁnition (separately for BSI, meningitis and RTI)
• Event does not meet case deﬁnition
Additional categories for analysis
9 To determine the appropriate category, the user should ﬁrst establish, whether
a  reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
the  deﬁnition is met, and there is evidence that the criteria of the next higher level
of  diagnostic certainty are met, the event should be classiﬁed in the next category.
This approach should be continued until the highest level of diagnostic certainty
for a given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the  event should be classiﬁed in additional categories four or ﬁve.
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(4) Reported neonatal infection (separately for BSI, meningi-
tis and RTI) with insufﬁcient evidence to meet the case
deﬁnition10
(5) Not a case of neonatal infection11 neither BSI, meningitis or
RTI
The interval between maternal immunisation and reported
neonatal infection could be deﬁned as the interval from the
date/time of immunisation to the date/time of onset2 of the ﬁrst
signs consistent with the deﬁnition. The timing of onset of a neona-
tal infection may  be deﬁned by the age of the infant at the time of
onset using speciﬁc periods of infancy as follows:
Periods of infancy for age of clinical recognition of a neonatal
infection
Time period Days
Prenatal <Day 1 of life
Neonatala 1–27b
Early neonatala 1–6b
Late neonatala 7–27
Post neonatal 28–364
a Use either Neonatal or divide into early neonatal and late neonatal.
b Day 1 = ﬁrst 24 h of life.
The duration of a possible neonatal infection could be analysed
as the interval between the date/time of onset2 of the ﬁrst signs
consistent with the deﬁnition and the end of episode5 and/or ﬁnal
outcome6. Whatever start and ending are used, they should be used
consistently within and across study groups.
If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magnitude of
the adverse experience could be used as the basis for analysis. Anal-
ysis may  also include other characteristics like qualitative patterns
of criteria deﬁning the event.
The distribution of data (as numerator and denominator data)
could be analysed in predeﬁned increments (e.g. measured val-
ues, times), where applicable. Increments speciﬁed above should
be used. When only a small number of cases is presented, the
respective values or time course can be presented individually.
Data on neonatal infections obtained from neonates born to
women vaccinated during pregnancy should be compared with
those obtained from an appropriately selected and documented
control group(s) or known background rates of neonatal infections
in comparable populations, and should be analysed by study arm
and dose where possible, e.g. in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the pre-
sentation and publication of data on neonatal infections following
maternal immunisation to allow for comparability of data, and
are recommended as an addition to data presented for the spe-
ciﬁc study question and setting. Additionally, it is recommended to
refer to existing general guidelines for the presentation and pub-
lication of randomised controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g. state-
ments of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomised
controlled trials (QUORUM), and of Meta-analysis Of Observa-
tional Studies in Epidemiology (MOOSE), respectively) and the
10 If the evidence available for an event is insufﬁcient because information is
missing, such an event should be categorised as “Reported neonatal infection with
insufﬁcient evidence to meet the case deﬁnition”.
11 An event does not meet the case deﬁnition if investigation reveals a negative
ﬁnding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classiﬁed as “Not a case of neonatal infection”.
Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE) and Strengthening the Reporting of Observational
Studies in Epidemiology for Newborn Infection (STROBE-NI) guide-
lines (Fitchett, in press) (http://www.equator-network.org).
All reported events of neonatal infections should be presented
according to the categories listed above.
Data on possible neonatal infections events should be presented
in accordance with data collection guidelines and data analysis
guidelines.
Terms to describe neonatal infection such as “low-grade”,
“mild”, “moderate”, “severe” or “signiﬁcant” are highly subjective,
prone to wide interpretation, and should be avoided, unless clearly
deﬁned.
Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available. It should be clear if
the denominator represents a population denominator (live births)
or neonates admitted to a facility. The source of the denominator
data should be reported and calculations of estimate described (e.g.
manufacturer data like total doses distributed, reporting through
Ministry of Health, coverage/population based data, etc.).
The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
If the distribution of data is skewed, median and interquartile
range are usually the more appropriate statistical descriptors than
the mean. However, the mean and standard deviation should also
be provided.
Any publication of data on neonatal infection should include a
detailed description of the methods used for data collection and
analysis as possible. It is essential to specify:
• The study design;
• The method, frequency and duration of monitoring for neonatal
infection;
• The trial proﬁle, indicating participant ﬂow during a study includ-
ing drop-outs and withdrawals to indicate the size and nature of
the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardised question-
naire, diary card, report form);
• Whether the day of immunisation was  considered “day one” or
“day zero” in the analysis;
• Whether the date of onset2 and/or the date of ﬁrst observation3
and/or the date of diagnosis4 was used for analysis; and
• Use of this case deﬁnition, in the abstract or methods section of
a publication.12
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